160 related articles for article (PubMed ID: 25619841)
1. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
Ruiz-Saenz A; Sandhu M; Carrasco Y; Maglathlin RL; Taunton J; Moasser MM
Oncogene; 2015 Oct; 34(41):5288-94. PubMed ID: 25619841
[TBL] [Abstract][Full Text] [Related]
2. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Kazemi S; Kawaguchi S; Badr CE; Mattos DR; Ruiz-Saenz A; Serrill JD; Moasser MM; Dolan BP; Paavilainen VO; Oishi S; McPhail KL; Ishmael JE
Biochem Pharmacol; 2021 Jan; 183():114317. PubMed ID: 33152346
[TBL] [Abstract][Full Text] [Related]
3. Secretory protein profiling reveals TNF-α inactivation by selective and promiscuous Sec61 modulators.
Maifeld SV; MacKinnon AL; Garrison JL; Sharma A; Kunkel EJ; Hegde RS; Taunton J
Chem Biol; 2011 Sep; 18(9):1082-8. PubMed ID: 21944747
[TBL] [Abstract][Full Text] [Related]
4. A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum.
Garrison JL; Kunkel EJ; Hegde RS; Taunton J
Nature; 2005 Jul; 436(7048):285-9. PubMed ID: 16015336
[TBL] [Abstract][Full Text] [Related]
5. Decatransin, a new natural product inhibiting protein translocation at the Sec61/SecYEG translocon.
Junne T; Wong J; Studer C; Aust T; Bauer BW; Beibel M; Bhullar B; Bruccoleri R; Eichenberger J; Estoppey D; Hartmann N; Knapp B; Krastel P; Melin N; Oakeley EJ; Oberer L; Riedl R; Roma G; Schuierer S; Petersen F; Tallarico JA; Rapoport TA; Spiess M; Hoepfner D
J Cell Sci; 2015 Mar; 128(6):1217-29. PubMed ID: 25616894
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1.
Besemer J; Harant H; Wang S; Oberhauser B; Marquardt K; Foster CA; Schreiner EP; de Vries JE; Dascher-Nadel C; Lindley IJ
Nature; 2005 Jul; 436(7048):290-3. PubMed ID: 16015337
[TBL] [Abstract][Full Text] [Related]
7. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
8. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
[TBL] [Abstract][Full Text] [Related]
9. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
10. Global signal peptide profiling reveals principles of selective Sec61 inhibition.
Wenzell NA; Tuch BB; McMinn DL; Lyons MJ; Kirk CJ; Taunton J
Nat Chem Biol; 2024 Mar; ():. PubMed ID: 38519575
[TBL] [Abstract][Full Text] [Related]
11. An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate.
Mackinnon AL; Paavilainen VO; Sharma A; Hegde RS; Taunton J
Elife; 2014; 3():e01483. PubMed ID: 24497544
[TBL] [Abstract][Full Text] [Related]
12. The ribosome quality control pathway can access nascent polypeptides stalled at the Sec61 translocon.
von der Malsburg K; Shao S; Hegde RS
Mol Biol Cell; 2015 Jun; 26(12):2168-80. PubMed ID: 25877867
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the Sec61 Complex and Novel High Throughput Screening Strategies to Target the Protein Translocation Pathway.
Pauwels E; Schülein R; Vermeire K
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769437
[TBL] [Abstract][Full Text] [Related]
14. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
16. Use of a sequential high throughput screening assay to identify novel inhibitors of the eukaryotic SRP-Sec61 targeting/translocation pathway.
Klein W; Rutz C; Eckhard J; Provinciael B; Specker E; Neuenschwander M; Kleinau G; Scheerer P; von Kries JP; Nazaré M; Vermeire K; Schülein R
PLoS One; 2018; 13(12):e0208641. PubMed ID: 30543669
[TBL] [Abstract][Full Text] [Related]
17. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
18. HER3 as a Therapeutic Target in Cancer.
Karachaliou N; Lazzari C; Verlicchi A; Sosa AE; Rosell R
BioDrugs; 2017 Feb; 31(1):63-73. PubMed ID: 28000159
[TBL] [Abstract][Full Text] [Related]
19. Eeyarestatin Compounds Selectively Enhance Sec61-Mediated Ca
Gamayun I; O'Keefe S; Pick T; Klein MC; Nguyen D; McKibbin C; Piacenti M; Williams HM; Flitsch SL; Whitehead RC; Swanton E; Helms V; High S; Zimmermann R; Cavalié A
Cell Chem Biol; 2019 Apr; 26(4):571-583.e6. PubMed ID: 30799222
[TBL] [Abstract][Full Text] [Related]
20. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
